It could be another depressing case of follow-the-leader drug development where drug companies rush to test a similar compounds class because everyone else is doing it, only to find out in the end that none of them work very well.
FORBES: Amgen Exec: "Clearly Superior" Prostate Cancer Drug Will Be Huge